Equity in Precision Medicine

General information


FREE registration for all HCA members who have signed up for the 2022 Conference package.

Registration deadline: 2pm, Friday 4th February

Equity in Precision Medicine

Key speaker:     Professor Rob Bristow (The Christie)
Panel member:  Dr Lovett Evan Reddick (AstraZeneca)
Panel member:  Dr Sommer Bazuro (FCB Health)
Moderator:        Kirsten Parr (CMC Connect, McCann Health Medical Communications)

Our first HCA Conference session of 2022 will kick off with Professor Rob Bristow, Chief Academic Officer at The Christie NHS Foundation Trust and one of the world’s leaders in oncology, who will share his thoughts on the future of precision medicine. 

COVID-19 has highlighted many inequalities in healthcare provision and outcomes. This session will take us through some of the lessons learned from this and the importance of digital platforms, enriched data and engagement with the wider community to ensure that precision medicine is an option for all rather than just the “chosen few”.  With a focus on local, national and international goals, Rob will provide a valuable insight into what the next 10 years could look like.

Following Rob's presentation, there will be a panel discussion with Lovett Evan Reddick, Global Medical Affairs Leader, AstraZeneca, and Sommer Bazuro, Chief Medical Officer, FCB Health.


Professor Rob Bristow, Director of the Manchester Cancer Research Centre

Robert Bristow joined the University of Manchester as Director of the Manchester Cancer Research Centre (MCRC) in August 2017 with a remit to developing a new cancer strategy for Manchester with a cancer team science approach. The MCRC is a unique partnership between Cancer Research UK, The University of Manchester and the Christie NHS Foundation Trust.  The strategy pulls together scientists, clinicians and patients to co-create scientific projects and trials with a focus on inclusion and under-served populations  at the intersection of social deprivation,  comorbidity, polypharmacy and ethnicity.

His primary research interests are in tumour hypoxia, DNA damage signalling and repair in tumours, and the genomics of prostate cancer progression and cancer treatment response. He is particularly interested in novel clinical trials that intensify cancer therapy to prostate cancer patients whose tumours harbour aggressive genetic changes and hypoxic sub-regions. Professor Bristow is currently a senior group leader in Translational Oncogenomics at the CRUK Manchester Institute and was the lead PI for the Canadian component of the ICGC whole genome prostate cancer sequencing project (CPC-GENE).

He has served on a number of senior Scientific Advisory Boards and committees for: Prostate Cancer Foundation (USA), the MOVEMBER Foundation, the American Association for Cancer Research (AACR), the German Cancer Centre, Tuebingen Comprehensive Cancer Centre, NKI Amsterdam, the Danish Cancer Society and sits on the Scientific Executive Board for Cancer Research UK (CRUK). He has over 280 published papers and book chapters and is twice a Canadian Foundation for Innovation (CFI) awardee. He was made a Canadian Cancer Society Research Scientist in 2004, an ESTRO Honorary Fellow in 2011 and a Fellow of the Academy of Sciences (UK) in 2019.

Lovett Evan Reddick, Global Medical Affairs Leader, AstraZeneca
Evan was a scholarship athlete in college at the University of Tennessee and earned PhDs in biophysics and biochemistry at the Center for Excellence in Structural Biology at Oak Ridge National Laboratory. Dr. Reddick was recruited to UT Southwestern Medical Center in Dallas, TX as an NIH Fellow studying the molecular basis of cancer. Following his fellowship, Dr. Reddick joined AstraZeneca Pharmaceuticals and has held multiple roles of increasing responsibility. He is currently a Global Medical Affairs Leader in the DNA Damage Franchise. His opinions are his own and his views do not necessarily represent those of his employer.

Sommer Bazuro, Chief Medical Officer, FCB Health
As the lead for the FCB Health Medical team, Sommer has over 16 years of experience in academia, medical communications, and promotional advertising, with 12 years at FCB Health. Sommer holds a PhD in cell growth and cancer from the University of Pennsylvania Medical School, a BS-Research Intensive in molecular biology from Yale University and was a postdoctoral research fellow with Memorial Sloan Kettering Cancer Center. She is a member of ASCO, The Lustgarten Board of Directors and served on the board of Susan G Komen greater NYC.

How to Book

All members who have signed up to the HCA Conference package will qualify for a free place at this event.  Please login to activate your free place - which will appear online at point of booking for those members who qualify. 

Registration Deadline: 2pm, Friday 4th February

This session is kindly sponsored by McCann Health.



£25.00 per person (ex. VAT)

£25.00 per person (ex. VAT)

£25.00 per person (ex. VAT)

£50.00 per person (ex. VAT)
You will need to register on this site in order to book any HCA events. Click here to register or login as a member or non-member.
Equity in Precision Medicine


Mon 07 Feb 2022

1:00 PM - 2:30 PM GMT
(2:00 PM - 3:30 PM CET)